Diabetic microvascular complications: possible targets for improved macrovascular outcomes

References

• The Diabetes Control and Complications Trial Research GroupThe effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitusN Engl J Med1993329149779868366922
   PubMed Web of Science ®Google Scholar
• LewisEHunsickerLGBainRPRohdeRDThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropathyN Engl J Med199332920145614628413456
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) GroupIntensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)Lancet199835291318378539742976
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) GroupTight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38BMJ199831771607037139732337
   PubMed Web of Science ®Google Scholar
• GersteinHCMillerMEACCORD Study GroupEffects of intensive glucose lowering in type 2 diabetesN Engl J Med2008358242545255918539917
   PubMed Web of Science ®Google Scholar
• CushmanWCEvansGWACCORD Study GroupEffects of intensive blood-pressure control in type 2 diabetes mellitusN Engl J Med20103621575158520228401
   PubMed Web of Science ®Google Scholar
• WolfGZiyadehFNHelmchenUZahnerGSchroederRStahlRAANG II is a mitogen for a murine cell line isolated from medullary thick ascending limb of Henle’s loopAm J Physiol19952685 Pt 2F940F9477771522
   PubMed Web of Science ®Google Scholar
• ZiyadehFNSharmaKEricksenMWolfGStimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-betaJ Clin Invest19949325365428113392
   PubMed Web of Science ®Google Scholar
• MauerMZinmanBGardinerRRenal and retinal effects of enalapril and losartan in type 1 diabetesN Engl J Med20093611405119571282
   PubMed Web of Science ®Google Scholar
• PerssonFRossingPHovindPIrbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudyDiabetes200655123550355517130503
   PubMed Web of Science ®Google Scholar
• FurumatsuYNagasawaYTomidaKEffect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blockerHypertens Res2008311596718360019
   PubMed Web of Science ®Google Scholar
• MehdiUFAdams-HuetBRaskinPVegaGLTotoRDAddition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathyJ Am Soc Nephrol200920122641265019926893
   PubMed Web of Science ®Google Scholar
• D’EliaJAWeinrauchLAGleasonRELipinskaIPendseSRoshanBLeeATToflerGFibrinogen and factor VII levels improve with glycemic control in patients with type 1 diabetes mellitus who have microvascular complicationsArch Intern Med200116119810111146704
   PubMedGoogle Scholar
• AokiTTBenbarkaMMOkimuraMCLong-term intermittent intravenous insulin therapy and type 1 diabetes mellitusLancet199334288705155188102666
   PubMed Web of Science ®Google Scholar
• AokiTTGrecuEOArcangeliMAChronic intermittent intravenous insulin therapy corrects orthostatic hypotension of diabetesAm J Med19959966836847503093
   PubMed Web of Science ®Google Scholar
• AokiTTGrecuEOPrendergastJJArcangeliMAMeisenheimerREffect of chronic intermittent intravenous insulin therapy on antihypertensive medication requirements in IDDM subjects with hypertension and nephropathyDiabetes Care1995189126012658612440
   PubMed Web of Science ®Google Scholar
• DaileyGEBodenGHCreechRHJohnsonDGleasonREKennedyFPWeinrauchLAWeirMD’EliaJEffects of pulsatile intravenous insulin therapy on the progression of diabetic nephropathyMetabolism200049111491149511092517
   PubMed Web of Science ®Google Scholar
• WeinrauchLABurgerAJAepfelbacherFLeeATGleasonRED’EliaJAA pilot study to test the effect of pulsatile insulin infusion on cardiovascular mechanisms that might contribute to attenuation of renal compromise in type 1 diabetes mellitus patients with proteinuriaMetabolism200756111453145717950093
   PubMed Web of Science ®Google Scholar
• WeinrauchLAGleasonRED’EliaJAWhat have trials of pulsatile intravenous insulin taught us?Metabolism2010595764765
   Web of Science ®Google Scholar
• NiswenderKEarly and aggressive initiation of insulin therapy for type 2 diabetes: what is the evidence?Clin Diabetes20092726068
   Google Scholar
• HolmanRRPaulSKBethelMAMatthewsDRNeilHA10-year follow-up of intensive glucose control in type 2 diabetesN Engl J Med2008359151577158918784090
   PubMed Web of Science ®Google Scholar
• AepfelbacherFCYeonSBWeinrauchLAD’EliaJBurgerAJImproved glycemic control induces regression of left ventricular mass in patients with type 1 diabetes mellitusInt J Cardiol2004941475114996474
   PubMed Web of Science ®Google Scholar
• SpiroMJKumarBRCrowleyTJMyocardial glycoproteins in diabetes: type VI collagen is a major PAS-reactive extracellular matrix proteinJ Moll Cell Cardiol1992244397410
   Web of Science ®Google Scholar
• D’EliaJAWeinrauchLAHealyRWLibertinoJABradleyRFLelandOSJrMyocardial dysfunction without coronary artery disease in diabetic renal failureAm J Cardiol1979432193199153711
   PubMed Web of Science ®Google Scholar
• BurgerAJWeinrauchLAD’EliaJAAronsonDEffect of glycemic control on heart rate variability in type I diabetic patients with cardiac autonomic neuropathyAm J Cardiol199984668769110498140
   PubMed Web of Science ®Google Scholar
• WeinrauchLABurgerAGleasonRELeeATD’EliaJALeft ventricular mass reduction in type 1 diabetic patients with nephropathyJ Clin Hypertens (Greenwich)20057315916415785157
   PubMedGoogle Scholar
• WeinrauchLABaylissGGleasonRELeeATD’EliaJAUtilization of an abbreviated diabetes impact management scale to assess change in subjective disability during a trial of pulsatile insulin delivery demonstrates benefitMetabolism200958448849119303968
   PubMed Web of Science ®Google Scholar
• Duran-JimenezBDoblerDMoffattSAdvanced glycation end products in extracellular matrix proteins contribute to the failure of sensory nerve regeneration in diabetesDiabetes200958122893290319720799
   PubMed Web of Science ®Google Scholar
• QuattriniCTavakoliMJeziorskaMSurrogate markers of small fiber damage in human diabetic neuropathyDiabetes20075682148215417513704
   PubMed Web of Science ®Google Scholar
• MehraSTavakoliMKallinikosPACorneal confocal microscopy detects early nerve regeneration after pancreas transplantation in patients with type 1 diabetesDiabetes Care200730102608261217623821
   PubMed Web of Science ®Google Scholar
• ChaturvediNPortaMKleinREffect of candesartan on prevention (DIRECT-Prevent 1) and progression (Direct-Protect 1) of retinopathy in type 1 diabetes: randomized, placebo-controlled trialsLancet200837296471394140218823656
   PubMed Web of Science ®Google Scholar
• ChaturvediNSjolieAKStephensonJMEffect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID study group. EURODIAB controlled trial of lisinopril in insulin dependant diabetes mellitusLancet1998351909528319433426
   PubMed Web of Science ®Google Scholar
• SjolieAKleinRPortaMEffect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomized placebo-controlled trialLancet200837296471385139318823658
   PubMed Web of Science ®Google Scholar
• BeulensJWPatelAVingerlingJREffects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trialDiabetologia200952102027203619633827
   PubMed Web of Science ®Google Scholar
• HanssonLZanchettiACarruthersSGEffects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trialLancet19983519118175517629635947
   PubMed Web of Science ®Google Scholar
• DevarajSCheungATJialalIEvidence of increased inflammation and microcirculatory abnormalities in patients with type 1 diabetes and their role in microvascular complicationsDiabetes200756112790279617686944
   PubMed Web of Science ®Google Scholar
• GardnerTWSanderBLarsenMLAn extension of the Early Treatment Diabetic Retinopathy Study (ETDRS) system for grading of diabetic macular edema in the astemizole retinopathy trialCurr Eye Res200631653554716769613
   PubMed Web of Science ®Google Scholar
• SilvaKCRosalesMABBiswasSKLopes de FariaJBLopes de FariaJMDiabetic retinal neurodegeneration is associated with mitochondrial oxidative stress and is improved by an angiotensin receptor blocker in a model combining hypertension and diabetesDiabetes20095861382139019289456
   PubMed Web of Science ®Google Scholar
• Early Treatment Diabetic Retinopathy Study GroupFundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12Opthalmology199198Suppl 5823833
   Web of Science ®Google Scholar
• WeinrauchLASunJGleasonREBodenGHCreechRHDaileyGKennedyFPWeirMRD’EliaJAPulsatile intermittent intravenous insulin therapy for attenuation of retinopathy and nephropathy in type 1 diabetes mellitusMetabolism201059101429143420189608
   PubMed Web of Science ®Google Scholar
• WeinrauchLASunJGleasonREBodenGHCreechRHDaileyGKennedyFPWeirMRD’EliaJAProgression of retinopathy in type 1 diabetic patients with nephropathy: impact of glycemia control as measured by variation in glycohemoglobin A1CJ Am Soc Nephrol.200920 Abstract.
   Google Scholar
• WadenJForsblomCThornLMGordinDSaraheimoMGroopP-HA1C variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetesDiabetes200958112649265519651819
   PubMed Web of Science ®Google Scholar
• KilpatrickESRigbyASAtkinSLA1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications TrialDiabetes Care200831112198220218650371
   PubMed Web of Science ®Google Scholar
• FlammerAJHermannFWiesliPEffect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertensionJ Hypertens200725478579117351370
   PubMed Web of Science ®Google Scholar
• KramerCSunkomatJWitteJAngiotensin II receptor-independent anti-inflammatory and antiaggregatory properties of losartan: role of active metabolite EXP3179Circ Res200290777077611964369
   PubMed Web of Science ®Google Scholar
• FortunoABidegainJRobadorPLosartan metabolite EXP3179 blocks NADPH oxidase-mediated superoxide production by inhibiting protein kinase C: potential clinical implications in hypertensionHypertension200954474475019687351
   PubMed Web of Science ®Google Scholar
• QuditGYLiuGCZhongJHuman recombinant ACE2 reduces the progression of diabetic nephropathyDiabetes201059252953819934006
   PubMed Web of Science ®Google Scholar
• SharmaHSvan HeugtenHAGoedbloedMAVerdouwPDLamersJMAngiotensin II induced expression of transcription factors precedes increase in transforming growth factor-beta 1 mRNA in neonatal cardiac fibroblastsBiochem Biophys Res Commun199420511051127999008
   PubMed Web of Science ®Google Scholar
• MaLJNakamuraSAldigierJCRegression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1J Am Soc Nephrol200516496697615728787
   PubMed Web of Science ®Google Scholar
• OnozatoMLTojoAKobayashiNGotoAMatsuokaHFujitaTDual blockade of aldosterone and angiotensin II additively suppresses TGF-beta and NADPH oxidase in the hypertensive kidneyNephrol Dial Transplant20072251314132217324946
   PubMed Web of Science ®Google Scholar
• NemethZKokenyGGodoMIncreased renoprotection with ACE inhibitor plus aldosterone antagonist as compared to montherapies – the effect on podocytesNephrol Dial Transplant200924123640365119666910
   PubMed Web of Science ®Google Scholar
• AgarwalRVitamin D, proteinuria, diabetic nephropathy, and progression of CKDClin J Am Soc Nephrol2009491523152819478099
   PubMed Web of Science ®Google Scholar
• ZhangYKongJDebDKChangALiYCVitamin D receptor attenuates renal fibrosis by suppressing the renin-angiotensin systemJ Am Soc Nephrol201021696697320378820
   PubMed Web of Science ®Google Scholar
• MizobuchiMNakamuraHTokumotoMMyocardial effects of VDR activators in renal failureJ Steroid Biochem Mol Biol20101211–218819220236614
   PubMed Web of Science ®Google Scholar
• AvendanoGFAgarwalRKBasheyRIEffects of glucose intolerance on myocardial function and collagen-linked glycationDiabetes19994871443144710389851
   PubMed Web of Science ®Google Scholar
• GrudenGThomasSBurtDMechanical stretch induces vascular permeability factor in human mesangial cells: mechanisms of signal transductionProc Natl Acad Sci U S A1997942212112121169342371
   PubMed Web of Science ®Google Scholar
• KimHWKimJLLeeHKHurDYYunIHKimSDEnalapril alters expression of key growth factors in experimental diabetic retinopathyCurr Eye Res2009341197698719958114
   PubMed Web of Science ®Google Scholar
• ZhengZChenHXuXLiCGuQEffects of angiotensin-converting enzyme inhibitors and beta adrenergic blockers on retinal vascular endothelial growth factor expression in rat diabetic retinopathyExp Eye Res200784474575217303121
   PubMed Web of Science ®Google Scholar
• FukumotoMTakaiSIshizakiEInvolvement of angiotensin II-dependent vascular endothelial growth factor gene expression via NADPH oxidase in the retina in a type 2 diabetic rat modelCurr Eye Res2008331088589118853323
   PubMed Web of Science ®Google Scholar
• KimJHKimJHYuYSChoCSKimKWBlockade of angiotensin II attenuates VEGF-medicated blood-retinal barrier breakdown in diabetic retinopathyJ Cereb Blood Flow Metab200929362162819107135
   PubMed Web of Science ®Google Scholar
• Wilkinson-BerkaJLTanGJaworskiKMillerAGIdentification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathologyCirc Res2009104112413319038868
   PubMed Web of Science ®Google Scholar
• LeopoldJADamAMaronBAAldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activityNat Med200713218919717273168
   PubMed Web of Science ®Google Scholar
• WatanabeTSuzukiJYamawakiHSharmaVKSheuSSBerkBCLosartan metabolite EXP3179 activates Akt and endothelial nitric oxide synthase via vascular endothelial growth factor receptor-2 in endothelial cells: angiotensin II type 1 receptor-independent effects of EXP3179Circulation2005112121798180516172287
   PubMed Web of Science ®Google Scholar
• MichelFAmbroisineMLDuriezMDelcayreCLevyBSilvestreJSAldosterone enhances ischemia-induced neovascularization through angiotensin II-dependent pathwayCirculation2004109161933193715078792
   PubMed Web of Science ®Google Scholar
• ParvingHHBrennerBMMcMurrayJJAliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE): rationale and study designNephrol Dial Transplant20092451663167119145003
   PubMed Web of Science ®Google Scholar
• LacyPEHowellSLYoungDAFinkCJNew hypothesis of insulin secretionNature19682195159117711794877537
   PubMed Web of Science ®Google Scholar
• OrciLGabbayKMalaisseWJPancreatic beta-cell web: it’s possible role in insulin secretionScience197217526112811304551150
   PubMed Web of Science ®Google Scholar
• VermaRKovariISoofiANihalaniDPatrieKHolzmanLBNephrin ectodomain engagement results in SRC kinase activation, nephrin phosphorylation, NCK recruitment, and actin polymerizationJ Clin Invest200611651346135916543952
   PubMed Web of Science ®Google Scholar
• CowardRJWelshGIKoziellANephrin is critical for the action of insulin on human glomerular podocytesDiabetes20075641127113517395751
   PubMed Web of Science ®Google Scholar
• FornoniAJeonJVarona SantosJNephrin is expressed on the surface of insulin vesicles and facilitates glucose-stimulated insulin releaseDiabetes201059119019919833886
   PubMed Web of Science ®Google Scholar
• JewellJLLuoWOhEWangZThurmondDCFilamentous actin regulates insulin exocytosis through direct interaction with syntaxin 4J Biol Chem200828316107161072618285343
   PubMed Web of Science ®Google Scholar
• WendtTTanjiNGuoJGlucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathyJ Am Soc Nephrol20031451383139512707408
   PubMed Web of Science ®Google Scholar
• ChuangPYYuQFangWUribarriJHeJCAdvanced glycation endproducts induce podocyte apoptosis by activation of the FOXO4 transcription factorKidney Int200772896597617667983
   PubMed Web of Science ®Google Scholar
• SaleemSZavadilJBaillyMThe molecular and functional phenotype of glomerular podocytes reveals key features of contractile smooth muscle cellsAm J Physiol Renal Physiol20082954F959F97018684887
   PubMed Web of Science ®Google Scholar
• SaitohYHongweiWUenoHMizutaMNakazatoMTelmisartan attenuates fatty-acid-induced oxidative stress and NAD(P)H oxidase activity in pancreatic beta-cellsDiabetes Metab200935539239719713141
   PubMed Web of Science ®Google Scholar
• ChuKYChengQChenCAngiotensin exerts glucose-dependent effects on Kv current in mouse pancreatic beta-cells via angiotensin II type 2 receptorsAm J Physiol20102982C313C323
   Web of Science ®Google Scholar
• MarchettiPDel GuerraSMarselliLPancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metforminJ Clin Endocrinol Metab200489115535554115531508
   PubMed Web of Science ®Google Scholar
• SasakiHAsanumaHFujitaMMetformin prevents progression of heart failure in dogs: role of AMP-activated protein kinaseCirculation2009119192568257719414638
   PubMed Web of Science ®Google Scholar
• HussainSRomioLSaleemMNephrin deficiency activates NF-kappaB and promotes glomerular injuryJ Am Soc Nephrol20092081733174319497968
   PubMed Web of Science ®Google Scholar
• SheerinNSA novel role for nephrin in the maintenance of glomerular structureJ Am Soc Nephrol20092081661166319590059
   PubMed Web of Science ®Google Scholar
• SharmaKRamachandra RaoSQuiGAdiponectin regulates albuminuria and podocyte function in miceJ Clin Invest200811851645165618431508
   PubMed Web of Science ®Google Scholar
• OuchiNKiharaSAritaYAdiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathwayCirculation2000102111296130110982546
   PubMed Web of Science ®Google Scholar
• BlancoSBonetJLopezDCasasIRomeroRACE inhibitors improve nephrin expression in Zucker rats with glomerulosclerosisKidney Int Suppl200593S10S1415613060
   PubMed Web of Science ®Google Scholar
• MichaelDXiongWGengXDrainPChowRHHuman insulin vesicle dynamics during pulsatile secretionDiabetes20075651277128817317765
   PubMed Web of Science ®Google Scholar
• PorksenNMunnSSteersJVeldhuisJButlerPCEffects of glucose ingestion versus infusion on pulsatile insulin secretion: the incretin effect is achieved by amplification of insulin secretory burst massDiabetes19964510131713238826965
   PubMed Web of Science ®Google Scholar
• JuhlCBPorksenNPincusSMHansenAPVeldhuisJDSchmitzOAcute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetesDiabetes20015081778178411473038
   PubMed Web of Science ®Google Scholar
• RitzelRSchulteMPorksenNGlucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose toleranceDiabetes200150477678411289042
   PubMed Web of Science ®Google Scholar
• MatthewsDRLangDABurnettMATurnerRCControl of pulsatile insulin secretion in manDiabetologia19832442312376345247
   PubMed Web of Science ®Google Scholar
• RosengrenAHJokubkaRTojjarDOverexpression of alpha 2 A-adrenergic receptors contributes to type 2 diabetesScience2010327596221722019965390
   PubMed Web of Science ®Google Scholar
• GribbleFMAlpha 2 A-adrenergic receptors and type 2 diabetesN Engl J Med2010362436136220107223
   PubMed Web of Science ®Google Scholar
• WeigleDSKoerkerDJGoodnerCJPulsatile glucagon delivery enhances glucose production by perifused rat hepatocytesAm J Physiol19842474 Pt 1E564E5686496673
   PubMed Web of Science ®Google Scholar
• LangDAMatthewsDRPetroJTurnerRCCyclic oscillations of basal plasma glucose and insulin concentrations in human beingsN Engl J Med19793011910231027386121
   PubMed Web of Science ®Google Scholar
• JaspanJBLeverEPolonskyKSvan CauterEIn vivo pulsatility of pancreatic islet peptidesAm J Physiol19862512 Pt 1E215E2262874743
   PubMed Web of Science ®Google Scholar
• LauTCarlssonPOLeungPSEvidence for a local angiotensingenerating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic isletsDiabetologia200447224024814722647
   PubMed Web of Science ®Google Scholar
• FliserDSchaeferFSchmidDVeldhuisJDRitzEAngiotensin II affects basal, pulsatile and glucose-stimulated insulin secretion in humansHypertension1997305115611619369270
   PubMed Web of Science ®Google Scholar
• BernankeDEpsteinFHMetabolism of the renal medullaAm J Physiol196520854154514264748
   PubMed Web of Science ®Google Scholar
• LeeJBVanceVKCahillGFJrMetabolism of C14-labeled substrates by rabbit kidney cortex and medullaAm J Physiol1962203273614463505
   PubMed Web of Science ®Google Scholar
• Martinez-MaldonadoMAllenJCEknoyanGSukiWSchwartzARenal concentrating mechanism: possible role for sodium-potassium activated adenosine triphosphataseScience19691658958078084240334
   PubMed Web of Science ®Google Scholar
• LeichtweissHLubbersDWeissCBaumgartlHRescheWThe oxygen supply of the rat kidney: measurements of intrarenal pO2Pfluegers Arch19693093283495816079
   PubMed Web of Science ®Google Scholar
• AuklandKKrogJRenal oxygen tensionNature196018867113685141
   PubMed Web of Science ®Google Scholar
• LilienfieldLSRoseJCLassenNADiverse distribution of red cells and albumin in the dog kidneyCirc Res19586681081513585610
   PubMed Web of Science ®Google Scholar
• AokiTTVlachokostaFVFossMCMeistasMTEvidence for restoration of hepatic glucose processing in type I diabetes mellitusJ Clin Invest19837148378396339560
   PubMed Web of Science ®Google Scholar
• JacobssonLTTuressonCGulfeATreatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritisJ Rheumatol20053271213121815996054
   PubMed Web of Science ®Google Scholar
• PorterKETurnerNACardiac fibroblasts: at the heart of myocardial remodelingPharmacol Ther2009123225527819460403
   PubMed Web of Science ®Google Scholar
• SekiguchiKLiXCokerMCross-regulation between the renin-angiotensin system and inflammatory mediators in cardiac hypertrophy and failureCadiovasc Res2004633433442
   Web of Science ®Google Scholar
• HwangMWMatsumoriAFurukawaYNeutralization of interleukin-1beta in the acute phase of myocardial infarction promotes the progression of left ventricular remodelingJ Am Coll Cardiol20013851546155311691538
   PubMed Web of Science ®Google Scholar
• FleschMHöperADell’ItaliaLActivation and functional significance of the reninangiotensin system in mice with cardiac restricted over-expression of tumor necrosis factorCirculation2003108559860412874189
   PubMed Web of Science ®Google Scholar
• NakamuraKKusanoKNakamuraYCarvedilol decreases elevated oxidative stress in human failing myocardiumCirculation2002105242867287112070115
   PubMed Web of Science ®Google Scholar
• MochizukiMYanoMOdaTScavenging free radicals by low-dose carvedilol prevents redox-dependent Ca2+ leak via stabilization of ryanodine receptor in heart failureJ Am Coll Cardiol200749161722173217448375
   PubMed Web of Science ®Google Scholar
• DelboscSCristolJPDescompsBMimranAJoverBSimvastatin prevents angiotensin II-induced cardiac alteration and oxidative stressHypertension200240214214712154104
   PubMed Web of Science ®Google Scholar
• MoeGWMarin-GarciaJKonigAGoldenthalMLuXFengQIn vivo TNF-alpha inhibition ameliorates cardiac mitochondrial dysfunction, oxidative stress, and apoptosis in experimental heart failureAm J Physiol Heart Circ Physiol20042874H1813H182015205165
   PubMed Web of Science ®Google Scholar
• LiSJiaoXTaoLTumor necrosis factor-alpha in mechanic trauma plasma mediates cardiomyocyte apoptosisAm J Physiol Heart Circ Physiol2007293H1847H185217616742
   PubMed Web of Science ®Google Scholar
• ValgimigliMMerliEMalaguttiPHydroxyl radical generation, levels of tumor necrosis factor-alpha, and progression to heart failure after acute myocardial infarctionJ Am Coll Cardiol200443112000200815172404
   PubMed Web of Science ®Google Scholar
• LerolleNBourgeoisSLevielFLebrunGPaillardMHouillierPAngiotensin II inhibits NaCl absorption in the rat medullary thick ascending limbAm J Physiol Renal Physiol20042873F404F41015100097
   PubMed Web of Science ®Google Scholar
• ShahidMFrancisJMajidDSTumor necrosis factor-alpha induces renal vasoconstriction as well as natriuresis in miceAm J Physiol Renal Physiol20082956F1836F184418922887
   PubMed Web of Science ®Google Scholar
• OgawaSMoriTNakoKKatoTTakeuchiKItoSAngiotensin II type 1 receptor blockers reduce oxidative stress markers in hypertensive diabetic nephropathyHypertension200647469970516505207
   PubMed Web of Science ®Google Scholar
• StokesMBFosterKMarkowitzGSDevelopment of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritisNephrol Dial Transplant20052071400140615840673
   PubMed Web of Science ®Google Scholar
• HirschIBBrownleeMBeyond hemoglobin A1c–need for additional markers of risk for diabetic microvascular complicationsJAMA2010303222291229220530784
   PubMed Web of Science ®Google Scholar